Pembrolizumab for brain infection in people with weakened immune systems
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This trial tests a drug called pembrolizumab for a rare brain infection called PML that happens when the immune system is weak. The drug may help the body fight the virus that causes PML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with PML within the last 2 months.
- You must have the JC virus in your spinal fluid.
- You must be able to give consent, or have someone who can give consent for you.
- You must agree to use effective birth control if you could become pregnant.
- Your immune system cannot be restored with other treatments (like for HIV or MS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests an IV medicine called brincidofovir for people with PML, a serious brain infection. The goal is to see if it can stop the virus from causing more damage.
This study follows people with suspected or confirmed progressive multifocal leukoencephalopathy (PML), people at higher risk, and healthy volunteers. It uses visits, brain imaging (MRI), and stored biological samples to better understand how PML progresses and who is at risk.
This study follows patients with chronic viral infections affecting the brain and spinal cord. Researchers will collect spinal fluid samples and track your health over one year to better understand these infections and improve care.
This Phase 1 study tests a small drug (called an anti–CD8+ T cell minibody) to see how much reaches the brain. It may help researchers understand how to deliver similar treatments for multiple sclerosis, progressive multifocal leukoencephalopathy (PML), or other brain inflammation when the brain’s protective barrier is “open.”
This study looks at people with multiple sclerosis who have taken Zeposia (ozanimod) and later developed a rare brain infection called PML. The goal is to understand how often this happens and to confirm cases.
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
Hear when a new Progressive Multifocal Leukoencephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.